Pala Diagnostics, LLC

Pala Diagnostics, LLC was paid $79K by Medicaid between Jul 2021 and Sep 2022, across 7 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 71% of everything it billed.

33Billing provider infoPALA DIAGNOSTICS, LLC
SAN DIEGO, CA 92121

33aNPI1720752538assigned 08/04/2021

33bProvider typeClinical Medical Laboratory

28Total paid$79K

24GClaims4,578

24DCodes billed7

24AFirst – last monthJul 2021 – Sep 2022

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#336 of 561

Median peer was paid$222K

This provider vs. median0.4×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2021	2,610	$23K
2022	1,968	$56K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	71%	1,602	720	$56K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	18%	1,404	651	$14K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	6.4%	669	289	$5K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	3.9%	217	132	$3K
99001		0%	291	154	$0.00
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	0%	133	63	$0.00
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	0%	262	137	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMCCOLLUM, KYLE (CFO)

Same official

Other billing entities under MCCOLLUM, KYLE

Full network →

Provider	Location	Paid
IV Services LLC	Metairie, LA	$354K
Empower Genomics Corp	Escondido, CA	$252K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.